Foetal growth restriction adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 5,958 adverse event reports that record the MedDRA preferred term Foetal growth restriction. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 423 reports in the 12 months to June 2026 and 380 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,065 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 423 (under 0.1%) record this term. Reports for patients aged 45 to 64 were 0.2% of the reports that record this term and 20% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 141 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Foetal growth restriction name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	83
Acetaminophen		59
Acetylsalicylic Acid		138
Alprazolam	Benzodiazepine	49
Amitriptyline hydrochloride	Tricyclic antidepressant	54
Amlodipine	Calcium channel blocker	84
Amoxicillin	Penicillin-class antibacterial	25
Aripiprazole	Atypical antipsychotic	29
Aspirin	Nonsteroidal anti-inflammatory drug	267
Atarax		35
Atenolol	beta-Adrenergic blocker	30
Azathioprine	Purine antimetabolite	204
Betamethasone		121
Bisoprolol	beta-Adrenergic blocker	171
Bisoprolol fumarate	beta-Adrenergic blocker	42
Bleomycin	Cytoprotective agent	27
Buprenorphine	Partial opioid agonist	46
Calcium		28
Carboplatin	Platinum-based drug	77
Ceftazidime	Cephalosporin antibacterial	31
Ceftriaxone	Cephalosporin antibacterial	62
Cefuroxime	Cephalosporin antibacterial	34
Certolizumab pegol	Tumor necrosis factor blocker	42
Ciclosporin		35
Cimzia	Tumor necrosis factor blocker	31
Cisplatin	Platinum-based drug	43
Citalopram	Serotonin reuptake inhibitor	39
Clexane		37
Combivir	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	41
Cyclophosphamide	Alkylating drug	205
Cyclosporine	Calcineurin inhibitor immunosuppressant	76
Cytarabine	Nucleoside metabolic inhibitor	51
Darbepoetin alfa	Erythropoiesis-stimulating agent	37
Darunavir	Protease inhibitor	41
Daunorubicin		26
Dexamethasone	Corticosteroid	177
Diazepam	Benzodiazepine	29
Diclofenac	Nonsteroidal anti-inflammatory drug	30
Dolutegravir		39
Doxorubicin	Anthracycline topoisomerase inhibitor	130
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	54
Enbrel	Tumor necrosis factor blocker	25
Enoxaparin		70
Enoxaparin sodium	Low molecular weight heparin	56
Epzicom		32
Escitalopram	Serotonin reuptake inhibitor	40
Esomeprazole	Proton pump inhibitor	54
Etoposide	Topoisomerase inhibitor	94
Fentanyl	Opioid agonist	28
Fluorouracil	Nucleoside metabolic inhibitor	37
Folic acid		102
Furosemide	Loop diuretic	107
Gabapentin	Anti-epileptic agent	49
Heparin		59
Human immunoglobulin g	Human immunoglobulin G	60
Humira		127
Hydralazine		30
Hydrocortisone	Corticosteroid	46
Hydroxychloroquine	Antimalarial	144
Hydroxyurea	Antimetabolite	31
Ibuprofen	Nonsteroidal anti-inflammatory drug	60
Ifosfamide	Alkylating drug	72
Insulin	Insulin analog	32
Iron		34
Isentress	Human immunodeficiency virus integrase strand transfer inhibitor	33
Kaletra	Cytochrome P450 3A inhibitor	48
Kardegic		26
Keppra		54
Kivexa		38
Labetalol	beta-Adrenergic blocker	85
Lamictal	Anti-epileptic agent	40
Lamivudine	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	63
Lamotrigine	Anti-epileptic agent	61
Levetiracetam		130
Levothyroxine		85
Lovenox	Low molecular weight heparin	73
Magnesium sulfate	Calculi dissolution agent	29
Makena		70
Mesalamine	Aminosalicylate	26
Mesna	Cytoprotective agent	44
Metformin	Biguanide	52
Methadone	Opioid agonist	56
Methotrexate	Folate analog metabolic inhibitor	88
Methyldopa	Central alpha-2 adrenergic agonist	161
Methylprednisolone	Corticosteroid	150
Metoclopramide	Dopamine-2 receptor antagonist	36
Metoprolol	beta-Adrenergic blocker	112
Midazolam	Benzodiazepine	25
Mirtazapine		33
Mycophenolate mofetil	Antimetabolite immunosuppressant	47
Nevirapine	Human immunodeficiency virus 1 Non-Nucleoside analog reverse transcriptase inhibitor	34
Nifedipine	Dihydropyridine calcium channel blocker	166
Norvir	Cytochrome P450 3A inhibitor	111
Novorapid		28
Omeprazole	Proton pump inhibitor	71
Ondansetron	Serotonin-3 receptor antagonist	76
Oxazepam	Benzodiazepine	82
Paclitaxel	Microtubule inhibitor	91
Pantoprazole	Proton pump inhibitor	64
Paracetamol		30
Plaquenil	Antimalarial	32
Potassium chloride	Osmotic laxative	32
Prednisolone	Corticosteroid	290
Prednisone	Corticosteroid	228
Prezcobix	Cytochrome P450 3A inhibitor	28
Prezista	Protease inhibitor	77
Progesterone	Progesterone	28
Propofol	General anesthetic	27
Propranolol	beta-Adrenergic blocker	80
Prozac	Serotonin reuptake inhibitor	27
Quetiapine	Atypical antipsychotic	58
Ranitidine	Histamine-2 receptor antagonist	34
Remicade	Tumor necrosis factor blocker	32
Reyataz	Protease inhibitor	64
Ritonavir	Cytochrome P450 3A inhibitor	43
Rituximab	CD20-directed cytolytic antibody	127
Seroquel	Atypical antipsychotic	27
Sertraline	Serotonin reuptake inhibitor	87
Sildenafil	Phosphodiesterase 5 inhibitor	37
Soliris	Complement inhibitor	37
Subutex		33
Sumatriptan	Serotonin-1b and Serotonin-1d receptor agonist	47
Tacrolimus	Calcineurin inhibitor immunosuppressant	190
Tenofovir disoproxil fumarate	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	54
Tivicay	Human immunodeficiency virus integrase strand transfer inhibitor	43
Topiramate		45
Trandate		55
Truvada	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	89
Tysabri	Integrin receptor antagonist	43
Valium	Benzodiazepine	32
Valproate sodium	Anti-epileptic agent	34
Valsartan	Angiotensin 2 receptor blocker	29
Vancomycin	Glycopeptide antibacterial	36
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	57
Venlafaxine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	25
Vinblastine		35
Vincristine		67
Zidovudine	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	51
Zofran		32
Zoloft	Serotonin reuptake inhibitor	30
Zopiclone		33

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 49 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Foetal growth restriction name, in order of name
Class	Reports with this term
Alkylating drug	305
Angiotensin 2 receptor blocker	103
Angiotensin converting enzyme inhibitor	51
Anthracycline topoisomerase inhibitor	197
Anti-epileptic agent	239
Antimalarial	199
Antimetabolite immunosuppressant	52
Atypical antipsychotic	273
Benzodiazepine	278
beta-Adrenergic blocker	616
Biguanide	73
Calcineurin inhibitor immunosuppressant	294
Calcium channel blocker	95
CD20-directed cytolytic antibody	135
Central alpha-2 adrenergic agonist	169
Cephalosporin antibacterial	171
Corticosteroid	975
Cytochrome P450 3A inhibitor	235
Cytoprotective agent	73
Dihydropyridine calcium channel blocker	209
Erythropoiesis-stimulating agent	81
Factor Xa inhibitor	52
Folate analog metabolic inhibitor	99
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	196
Histamine-2 receptor antagonist	52
Human immunodeficiency virus integrase strand transfer inhibitor	78
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	261
Human immunoglobulin G	92
Insulin analog	93
Integrin receptor antagonist	60
Loop diuretic	110
Low molecular weight heparin	129
Microtubule inhibitor	105
Nonsteroidal anti-inflammatory drug	375
Nucleoside metabolic inhibitor	111
Opioid agonist	166
Osmotic laxative	52
Partial opioid agonist	50
Platinum-based drug	137
Protease inhibitor	198
Proton pump inhibitor	245
Purine antimetabolite	218
Serotonin and norepinephrine reuptake inhibitor	109
Serotonin reuptake inhibitor	298
Serotonin-1b and Serotonin-1d receptor agonist	57
Serotonin-3 receptor antagonist	82
Topoisomerase inhibitor	101
Tricyclic antidepressant	54
Tumor necrosis factor blocker	185

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Foetal growth restriction, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Foetal growth restriction
Age	Reports	Share
Under 2	943	15.8%
2 to 11	22	0.4%
12 to 17	5	0.1%
18 to 44	655	11%
45 to 64	9	0.2%
65 to 74	0	0%
75 and over	0	0%
Age not given	4,324	72.6%

Sex of the patient in the reports that record Foetal growth restriction
Sex	Reports	Share
Female	2,565	43.1%
Male	1,412	23.7%
Unknown or not given	1,981	33.2%

Age and sex are as the report gives them. 20.5% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Foetal growth restriction: adverse event reports that record this term. https://reportedreactions.com/reaction/foetal-growth-restriction/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Foetal growth restriction mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page